SCHEMBL30983976

SCHEMBL30983976

CCOC(=O)COCCOc1ccc(-c2nc3c(OC4(C)CC4)ncnc3n2Cc2cccc(Cl)c2)c(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 2/20 0.36
▸ KMT2A Q03164 3/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ CNR1 P21554 3/20 0.34
▸ MAPT P10636 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ POLB P06746 1/20 0.33
▸ TLR7 Q9NYK1 2/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HTR6 P50406 2/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ KLKB1 P03952 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983880 1.00 MAOB (0.36) MAOBKMT2AMEN1CNR1MAPT
SCHEMBL30983422 0.92 PPARG (0.35) MAOBKMT2AMEN1CNR1PIK3CD
SCHEMBL31268778 0.92 PPARG (0.35) MAOBKMT2AMEN1CNR1PIK3CD
SCHEMBL31269342 0.89 PPARG (0.38) MAOBKMT2AMEN1CNR1PIK3CD
SCHEMBL31268992 0.89 CNR1 (0.35) MAOBKMT2AMEN1CNR1PIK3CD
SCHEMBL31268983 0.89 PPARG (0.37) MAOBCNR1PIK3CDTLR7HTR6
SCHEMBL30984034 0.88 PIK3CD (0.37) KMT2AMEN1CNR1MAPTALDH1A1
SCHEMBL31269035 0.87 CNR1 (0.36) MAOBKMT2AMEN1CNR1PIK3CD
SCHEMBL30983523 0.87 PLA2G2A (0.38) CNR1PIK3CDTLR7PLA2G2A
SCHEMBL30983451 0.86 PLA2G2A (0.38) MAOBCNR1PIK3CDTLR7PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB MAOB 2499/4885KMT2A 880/4885MEN1 3755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback